慢性丙型肝炎患者发生重度肝纤维化相关因素分析

doi:10.3969/j.issn.1672-5069.2017.04.025

Abstract

Zhang Ting, Zhang Hang, Hao Zheng, et al.. Risk factors of severe hepatic fibrosis in patients with hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 602-603.

[1] 姚轶男，黄鹏，陈红波，等. 江苏省句容市既往有偿献血人群慢性丙型肝炎重度肝纤维化影响因素研究. 中华流行病学杂志，2017，38（1）:49-52.
[2] 李杨，李爱华，庞琳. 医院慢性丙型病毒性肝炎患者进展性肝纤维化的发生率及影响因素研究. 中国艾滋病性病， 2015，16（5）:414-417.
[3] Schmid P，Bregenzer A，Huber M，et al. Progression of liver fibrosis in HIV/HCV co-infection:a comparison between non-invasive assessment methods and liver biopsy. PloS One，2015，10（9）:e0138838.
[4] 康姚洁，王煊. 慢性丙型肝炎病毒感染致糖代谢异常的相关机制研究进展. 实用肝脏病杂志，2014，17（1）：102-105.
[5] 莫思柏，罗贤鑫，陈廷宪. Fibroscan在慢性丙型肝炎肝纤维化的诊断价值及影响因素分析. 深圳中西医结合杂志，2016，26（20）:30-32.
[6] Pellicoro A，Ramachandran P， Iredale J P，et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol， 2014，14（3）:181-194.
[7] Vergniol J，Boursier J，Coutzac C，et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology，2014，60（1）:65-76.
[8] Berenguer M，Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C:mechanisms， assessment and treatment. J Hepatol，2013，58（5）: 1028-1041.
[9] 郭亚楠，李明珍，孙丽荣，等. 2 型糖尿病合并非酒精性脂肪性肝病血糖波动与非酒精性脂肪性肝病肝纤维化评分的相关性分析. 中国糖尿病杂志，2015，23（5）:412-414.
[10] 孙玉生，林波，王思谦，等. 慢性酒精摄入所致的肝细胞上皮-间充质转化参与小鼠肝纤维化形成. 中国病理生理杂志，2014，30（1）:77-84.

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[3]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[4]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[5]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[6]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[7]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[8]	Qiu Jun, Wang Xueqing, Zhang Bo, et al. Percutaneous choledocholithotomy for the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2019, 22(5): 744-747.
[9]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[10]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[11]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[12]	Zhang Wei, Shi Junmei, Wang Qian. Fisk factors for occurrence of hyperbilirubinemia in neonates [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 534-536.
[13]	Li Fang, Zou Guizhou, Ye Jun, et al. Clinical features and risk factors of patients with decompensated cirrhosis and sepsis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 557-560.
[14]	Zhou Liyun, Li Xiaotian, Li Li. 1,25（OH）₂D₃ inhibits hepatic fibrosis by regulating miR-146a levels in vitro and in vivo [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 333-336.
[15]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.

Risk factors of severe hepatic fibrosis in patients with hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments